Trial Profile
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2019
Price :
$35
*
At a glance
- Drugs 62Cu-ETS (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 23 Jun 2018 New trial record
- 05 Jun 2018 Results studying PET/CT Assessment of Tumor Perfusion presented at the 54th Annual Meeting of the American Society of Clinical Oncology